![]()
MIRA INFORM REPORT
|
Report Date : |
09.12.2011 |
IDENTIFICATION DETAILS
|
Name : |
GETZ PHARMA (PRIVATE) LIMITED |
|
|
|
|
Formerly Known As : |
SAITEX PHARMACEUTICALS (PRIVATE) LIMITED |
|
|
|
|
Registered Office : |
Plot # 30/31, Sector -
27, Korangi Industrial Area, Karachi |
|
|
|
|
Country : |
Pakistan |
|
|
|
|
Year of Establishment : |
1983 |
|
|
|
|
Com. Reg. No.: |
0010979 |
|
|
|
|
Legal Form : |
Private Limited Company |
|
|
|
|
Line of Business : |
Manufacture & Marketing of Pharmaceutical Products |
|
|
|
|
No. of Employees
: |
180 persons |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
Pakistan |
b2 |
b2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
GETZ PHARMA (PRIVATE) LIMITED
|
Registered Address
& Factory |
|
Plot # 30/31, Sector - 27, Korangi Industrial Area, Karachi, Pakistan |
|
Tel # |
92 (21) 35063100, 35063101, 35063102, 35057867 |
|
Fax # |
92 (21) 35060141 |
|
Email |
|
a. |
Nature of Business |
Manufacture & Marketing of Pharmaceutical Products |
|
b. |
Year Established |
1983 |
|
c. |
Registration # |
0010979 (Old Registration No.
was K-186/7711) |
|
|
|
|
In Lahore, Islamabad, Rawalpindi & Multan
Ford Rhodes Sidat Hyder & Co.
(Chartered
Accountants)
7th Floor, Progressive Plaza, Beaumont Road, Karachi, Pakistan
Subject Company was established by the name of “SAITEX PHARMACEUTICALS (PRIVATE) LIMITED” in 1983 then afterwards its name was changed to “GETZ PHARMA (PRIVATE) LIMITED”
|
Authorized Capital |
Rs. 150,000,000/- divided into 1,500,000 shares of Rs. 100/- each |
|
Issued & Paid up Capital |
Rs. 102,300,000/- divided into 1,023,000 shares of Rs. 100/- each |
|
Names |
Nationality |
Address |
Occupation |
Designation |
|
Mr. Khalid Mahmood Mr. Raymond Simkins Mr. Javed Ghulam Mohammad |
Pakistani British Pakistani |
House # 65/1, 3rd Street, Phase-V, D.H.A., Karachi Plot # 30/31, Sector - 27, Korangi Industrial Area, Karachi 404-B, Royal Apartments, KDA Scheme 1, Karachi |
Business Business Business |
Chief Executive Director Director |
|
Names |
No. of Shares |
|
M/s Development Holdings Asia Limited, Ansbacher House, 2nd Floor, East & Shirley Streets, North P.O. Box N-9934, Nassau, Bahamas |
1,023,000 |
A. Subsidiary
None
B. Associated Companies
(1) Getz Health (Private) Limited, Pakistan
ADVANT, ALLERGET, ALSEF, ASACOL, CELBEXX, CLARITEK,
COLPERMIN, ETIDOXINE, EZITA, FEXET, GETIFLOX, GETRYL, HILER, LEFLOX, LILAC,
LIPIGET, MALTOFER, MONTIGET, NEXUM, PANSLAY, PANTRA, PRAZ, RAPIGET, RIBAZOLE,
RISEK, SETNIZOLE, TRUPRIL, UNIFERON, ZOLID
180
The capacity and production of the Company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture
|
Year |
In Pak Rupees |
|
2010 - 2011 (Ending |
320,000,000/- (Estimated) |
(Foreign)
(1) CAPSUGEL (THAILAND) CO. LIMITED.
(2) MARS FINE CHEMICALS, SINGAPORE.
(3) ALCAN PACKAGING INC, GERMANY.
Mainly exist at all important cities of Pakistan
(1) Standard Chartered Bank Pakistan Limited, I.I. Chundrigar Road, Karachi, Pakistan.(Finance obtained PKR 150,000,000/-)
(2) Faysal Bank Limited, Trade Centre, I.I. Chundrigar Road, Karachi, Pakistan.( Finance obtained PKR 94,000,000/-)
(3) HSBC Bank Middle East Limited, M. R. Kiyani Road, Karachi, Pakistan.(Finance obtained PKR 67,000,000/-)
Sound
·
Pakistan Pharmaceutical Manufacturers
Association.(PPMA)
·
Karachi Chamber of Commerce & Industry.(KCCI)
|
Currency |
Unit |
Pakistani Rupee |
|
US Dollar |
1 |
Rs. 89.20 |
|
UK Pound |
1 |
Rs. 139.00 |
|
Euro |
1 |
Rs. 119.00 |
Subject is a
well-established Company having fine track. Trade relations are reported as fair. Payments are
usually correct and as per commitments. Subject can be considered for normal business
dealings at usual trade terms and conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.51.78 |
|
UK Pound |
1 |
Rs.81.32 |
|
Euro |
1 |
Rs.69.42 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit transaction.
It has above average (strong) capability for payment of interest and
principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with full
security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk and
to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.